Replication Stress Sensing Defects in Small Cell Lung Cancer
Official title: Replication Stress Sensing and Signaling Defects in SCLC
Funded at New York University School of Medicine · NIH-11390984 · Data updated 2026-11-12
A study in people might not be involved directly, but it aims to understand why a common lung cancer responds poorly to therapy over time by examining how cancer cells handle replication stress.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 16, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $350,490 |
| NIH project number | 5P01CA288368-03 |
| Project ID | NIH-11390984 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with small cell lung cancer whose tumors could be modeled or whose tumor biology aligns with SLFN11-related replication stress pathways.
✕Less likely to help
Patients whose cancer biology does not involve SLFN11 pathways or replication stress responses may derive little direct benefit.
What this research studies
This project looks at why small cell lung cancer (SCLC) is initially sensitive to chemotherapy but later becomes resistant, focusing on replication stress and DNA damage responses. Researchers will study SLFN11, a gene linked to sensitivity to DNA damage, and how its expression affects early replication stress responses by using cell models with mutant SLFN11 proteins. The work will distinguish immediate effects of SLFN11 from longer-term changes in the cell by examining protein levels and replication fork dynamics. Findings could reveal new ways to overcome resistance to chemotherapy in SCLC. The grant uses cell-based experiments to illuminate mechanisms that could guide future therapies.
Why it matters
Potential benefit: If successful, the research could identify new targets to prevent or delay chemotherapy resistance in SCLC, potentially improving treatment effectiveness.
How similar studies have gone: Prior studies have linked SLFN11 expression to chemotherapy sensitivity across several cancers, supporting potential translational impact.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Huang, Tony Tung — New York University School of Medicine
- Study coordinator: Huang, Tony Tung
Related research
Other NIH-funded projects on the same topics.
-
Role of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC in the Immunotherapy Era
This project looks at whether giving twice-daily radiotherapy for limited-stage small cell lung cancer still helps patients today who are also getting immunotherapy.
-
SCLC model creation and therapy testing
A cancer research program using mouse models and engineered human and mouse cells to study small cell lung cancer and test potential treatments.
-
Impact of genetic changes on SCLC subtypes and treatment response
This project explores how specific genetic changes in small cell lung cancer (SCLC) affect the disease and how it responds to targeted drugs.
-
Repair mechanisms for DNA lesions in small cell lung cancer
Researchers are studying how cancer cells with small cell lung cancer respond or become resistant to treatment by looking at the ways DNA damage is repaired.
-
Understanding how replication stress affects a hard-to-treat breast cancer gene patients may carry
This grant explores how certain breast cancer gene defects interact with replication stress to influence cancer cell survival and treatment resistance, with potential implications for therapies in patients with BRCA2-related breast cancer.
-
Targeting DHX9 to boost viral-like immune response in Small Cell Lung Cancer
A scientist team is testing whether blocking a protein called DHX9 can make aggressive small cell lung cancer more visible to the immune system and more responsive to immunotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.